EBS vs GSK · rev $390.4M vs P/E 13, $103.31B cap
Emergent Biosolutions Inc (EBS) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported EBS revenue for 2026-06-30 was $390.4M. Net income was -$173.4M. EBS currently screens at market cap $416.4M.
GSK does not have a complete income-statement cache yet.
EBS currently screens at market cap $416.4M. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the EBS and GSK stock pages for the full models.
Not investment advice.